Company Search:
Advanced Search
Sponsored Links
Solon Eiendom ASA Company Snapshot
Solon Eiendom ASA operates within the Pharmaceutical preparations sector. In addition to historical fundamental analyses, the complete report available to purchase compares Solon Eiendom ASA with three other pharmaceutical manufacturers in Europe: COSMO Pharmaceuticals SA of Italy (2016 sales of 67.66 million Euro [US$82.92 million] of which 53% was Manufacturing of MMX Products), Orexo Ab of Sweden (705.90 million Swedish Kronor [US$88.10 million] of which 68% was Zubsolv), and Antibiotice SA which is based in Romania (332.44 million Romanian Leu [US$87.90 million] ).

Sales Analysis. Sales increased substantially in 2016: During the year ended December of 2016, sales at Solon Eiendom ASA were NOK 691.50 million (US$87.74 million). This is an increase of 813,425.9% versus 2015, when the company's sales were NOK 85,000.00 .
Company ReportsSubscriptions
Looking For More?
Purchace an In-Depth Report
Solon Eiendom ASA
  Stock Performance Chart for Solon Eiendom ASA
  Stock Data: Recent Stock Performance:
  Current Price (1/12/2018): 20.95
(Figures in Norwegian Kroner)
1 Week -0.9%   13 Weeks 9.1%  
4 Weeks 11.4%   52 Weeks -25.2%  
Solon Eiendom ASA Key Data:
  Ticker: SOLON Country: Norway
  Exchanges: FRA LON OSL Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Pharmaceutical Preparations
  2016 Sales 691,497,000
(Year Ending Jan 2017).
Employees: 19
  Currency: Norwegian Kroner Market Cap: 1,018,066,253
  Fiscal Yr Ends: December Shares Outstanding: 48,595,048
  Share Type: Ordinaere Aksje Closely Held Shares: 32,814,376
Sponsored Links
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.